Trial Profile
A Single Armed Phase ⅡStudy of Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs Icotinib (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 30 Jun 2020 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.
- 06 Apr 2020 Planned End Date changed from 1 Apr 2017 to 1 Jun 2020.
- 06 Apr 2020 Status changed from not yet recruiting to active, no longer recruiting.